Pentoxifylline concentrate for solution for and / I / / 10 pieces b / a 20mg / ml 5ml ampoules


Pentoxifylline concentrate for solution for and / I / / 10 pieces b / a 20mg / ml 5ml ampoules



Active substance:
1 mL contains: pentoxifylline – 20.0 mg.
Product form:
Concentrate for solution for infusion of 20 mg / ml.
– Increased sensitivity to pentoxifylline, other xanthine derivatives or other components forming part of the formulation; – pronounced coronary or cerebral arteriosclerosis; – acute myocardial infarction; – The expressed disturbances of heart rhythm; – uncontrolled arterial hypotension; – massive bleeding; – bleeding in the retina of the eye; – bleeding in the brain; – pregnancy, lactation; – the age of 18 years (effectiveness and safety have been established).
20 mg / ml
– Peripheral circulatory disorders on the background of atherosclerosis, diabetes, and inflammatory processes (including with intermittent claudication due to atherosclerosis, diabetic angiopathy, obliterative endarteritis); – trophic disorders of tissues due to violation of the arterial and venous microcirculation (varicose ulcers, gangrene, frostbite); – angioneyropatii (paresthesia, akrozianoz, Raynaud’s disease); – chronic ischemic disorders of cerebral blood circulation type (including the cerebral atherosclerosis); – impaired circulation in the vessels of the eye (acute and chronic failure of blood supply of the mesh and vascular eye membranes); – abnormalities in the middle ear vascular origin, accompanied by hearing loss.
pharmachologic effect
Pharmacological group:
Vasodilating agent.
Pharmacological properties:
Pentoxifylline is a xanthine derivative. Improves microcirculation and blood rheology. The mechanism of action is associated with inhibition of phosphodiesterase, and an increase of cyclic adenosine monophosphate 3.5 (3.5 AMP) in platelets and adenosine triphosphate (ATP) in erythrocytes with simultaneous saturation of the energy potential, which in turn leads to vasodilation, some reduction in total peripheral vascular resistance , increase in systolic and minute blood volume without a significant change in heart rate. Slightly dilates coronary arteries. When administered intravenously, leads to increased collateral circulation, increase volume of blood flowing through a unit cross section. Leads to an increase in ATP content in the brain, a positive effect on the bioelectrical activity of the central nervous system. , Decreases viscosity of blood causes platelet disaggregation, increases the elasticity of red blood cells (due to the influence on pathologically altered erythrocyte deformability). Improves microcirculation in areas of impaired circulation. When peripheral arterial occlusive disease (intermittent claudication), leads to a lengthening of the distance walking, elimination of night leg cramps and pain at rest.
Conditions of supply of pharmacies
Dosing and Administration
Intravenously. During the infusion the patient should be in position “lying”. The usual dose is two intravenous infusion day (morning and afternoon), each of which contains 200 mg of pentoxifylline (2 ampoules 5 ml) or 300 mg of pentoxifylline (3 ampoules 5 ml) in 250 ml or 500 ml of 0.9% solution sodium chloride or Ringer solution.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review